Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab.
Camera S, Fornaro L, Rimini M, Persano M, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Salani F, Bozzarelli S, Corallo S, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Farinea G, Genovesi V, De Rosa A, Lavacchi D, Lo Prinzi F, Passeri L, Ferrara M, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Esposito L, Casadio C, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Bekaii-Saab T, Masi G, Vogel A, Lonardi S, Vivaldi C, Rimassa L, Casadei-Gardini A.
Camera S, et al. Among authors: spinelli gp.
Target Oncol. 2026 Mar;21(2):237-253. doi: 10.1007/s11523-026-01200-9. Epub 2026 Feb 27.
Target Oncol. 2026.
PMID: 41758293